Literature DB >> 14628073

NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration.

F E Nicolini1, J D Cashman, D E Hogge, R K Humphries, C J Eaves.   

Abstract

Transplantation of immunodeficient mice with human hematopoietic cells has greatly facilitated studies of the earliest stages of human hematopoiesis. These include demonstration of the ability of injected 'human-specific' hematopoietic growth factors to enhance the production of human cells at multiple levels of differentiation. In contrast, the effects of continuous exposure to such molecules have not been well investigated. Here, we show that nonobese diabetic severe combined immunodeficiency mice genetically engineered to produce ng/ml serum levels of human interleukin-3 (IL-3), granulocyte/macrophage-stimulating factor (GM-CSF) and Steel factor (SF) display a complex phenotype when transplanted with primitive human bone marrow (BM) or fetal liver cells. This phenotype is characterized by an enhancement of terminal human myelopoiesis and a matched suppression of terminal human erythropoiesis, with a slight reduction in human B-lymphopoiesis in the BM of the engrafted mice. Human clonogenic progenitors are more prevalent in the blood of the transplanted growth factor-producing mice and this is accompanied by a very marked reduction of more primitive human cells in the BM. Our findings suggest that long-term exposure of primitive human hematopoietic cells to elevated levels of human IL-3, GM-CSF and SF in vivo may deleteriously affect the stem cell compartment, while expanding terminal myelopoiesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14628073     DOI: 10.1038/sj.leu.2403222

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  60 in total

1.  The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids.

Authors:  Ayesh K Seneviratne; Mingjing Xu; Juan J Aristizabal Henao; Val A Fajardo; Zhenyue Hao; Veronique Voisin; G Wei Xu; Rose Hurren; S Kim; Neil MacLean; Xiaoming Wang; Marcela Gronda; Danny Jeyaraju; Yulia Jitkova; Troy Ketela; Michael Mullokandov; David Sharon; Geethu Thomas; Raphaël Chouinard-Watkins; James R Hawley; Caitlin Schafer; Helen Loo Yau; Zaza Khuchua; Ahmed Aman; Rima Al-Awar; Atan Gross; Steven M Claypool; Richard P Bazinet; Mathieu Lupien; Steven Chan; Daniel D De Carvalho; Mark D Minden; Gary D Bader; Ken D Stark; Paul LeBlanc; Aaron D Schimmer
Journal:  Cell Stem Cell       Date:  2019-03-28       Impact factor: 24.633

2.  Human hematopoietic stem cell maintenance and myeloid cell development in next-generation humanized mouse models.

Authors:  Trisha R Sippel; Stefan Radtke; Tayla M Olsen; Hans-Peter Kiem; Anthony Rongvaux
Journal:  Blood Adv       Date:  2019-02-12

3.  Engraftment of human HSCs in nonirradiated newborn NOD-scid IL2rγ null mice is enhanced by transgenic expression of membrane-bound human SCF.

Authors:  Michael A Brehm; Waldemar J Racki; Jean Leif; Lisa Burzenski; Vishnu Hosur; Amber Wetmore; Bruce Gott; Mary Herlihy; Ronald Ignotz; Raymond Dunn; Leonard D Shultz; Dale L Greiner
Journal:  Blood       Date:  2012-01-12       Impact factor: 22.113

Review 4.  Humanized mice for immune system investigation: progress, promise and challenges.

Authors:  Leonard D Shultz; Michael A Brehm; J Victor Garcia-Martinez; Dale L Greiner
Journal:  Nat Rev Immunol       Date:  2012-10-12       Impact factor: 53.106

5.  AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3.

Authors:  M Wunderlich; F-S Chou; K A Link; B Mizukawa; R L Perry; M Carroll; J C Mulloy
Journal:  Leukemia       Date:  2010-08-05       Impact factor: 11.528

6.  Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines.

Authors:  Yanyan Zhang; Liang He; Dorothée Selimoglu-Buet; Chloe Jego; Margot Morabito; Christophe Willekens; M'boyba Khadija Diop; Patrick Gonin; Valérie Lapierre; Nathalie Droin; Eric Solary; Fawzia Louache
Journal:  Blood Adv       Date:  2017-06-13

7.  High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression.

Authors:  Nicole L Wittwer; Gabriela Brumatti; Ceilidh Marchant; Jarrod J Sandow; Melanie K Pudney; Mara Dottore; Richard J D'Andrea; Angel F Lopez; Paul G Ekert; Hayley S Ramshaw
Journal:  Blood Adv       Date:  2017-06-20

8.  Comparison of Human Hematopoietic Reconstitution in Different Strains of Immunodeficient Mice.

Authors:  Ashley I Beyer; Marcus O Muench
Journal:  Stem Cells Dev       Date:  2016-10-27       Impact factor: 3.272

9.  A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.

Authors:  Mark Wunderlich; Courtney Stockman; Mahima Devarajan; Navin Ravishankar; Christina Sexton; Ashish R Kumar; Benjamin Mizukawa; James C Mulloy
Journal:  JCI Insight       Date:  2016-09-22

10.  Model systems for examining effects of leukemia-associated oncogenes in primary human CD34+ cells via retroviral transduction.

Authors:  Mark Wunderlich; James C Mulloy
Journal:  Methods Mol Biol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.